Search results
Showing 7366 to 7380 of 7710 results
This medtech innovation briefing has been replaced by NICE diagnostic guidance on heart failure algorithms for remote monitoring in people with cardiac implantable electronic devices.
Voxelotor for treating haemolytic anaemia caused by sickle cell disease (TA981)
NICE has withdrawn this guidance. Pfizer has informed the Medicines and Healthcare products Regulatory Agency (MHRA) that the product is being withdrawn. The recall notification is being shared with all healthcare professionals. No new people will start taking voxelotor in the UK. Healthcare professionals should discuss alternative treatment options with people currently having voxelotor.
Benralizumab for treating eosinophilic oesophagitis in people aged 12 to 65 [ID5093]
Discontinued [GID-TA10995]
Otilimab for treating moderate to severe rheumatoid arthritis [ID6171]
Discontinued [GID-TA11108]
Parsaclisib for treating relapsed or refractory marginal zone lymphoma [ID3976]
Discontinued [GID-TA10863]
Pembrolizumab with enzalutamide for treating metastatic hormone-relapsed prostate cancer [ID5103]
Discontinued [GID-TA11004]
Pembrolizumab with lenvatinib for previously treated metastatic colorectal cancer [ID5112]
Discontinued [GID-TA11020]
Filgotinib for treating moderately to severely active Crohn's disease [ID6236]
Discontinued [GID-TA11244]
Maribavir for cytomegalovirus infection after haematopoietic stem cell transplant [ID5075]
Discontinued [GID-TA10958]
Discontinued [GID-TA10525]